Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain

Objective: Endometriosis is a common gynecological condition that affects many women of reproductive age worldwide and is a major cause of pain and infertility. Treatment of endometriosis can be either surgical, aiming to restore normal anatomy by removing endometriotic lesions, or hormonal. Variou...

Full description

Saved in:
Bibliographic Details
Main Authors: Tolga Karacan, Huseyin Kiyak, Eser Ozyurek, Mevlide San, Engin Oral
Format: Article
Language:English
Published: Medical Network 2020-12-01
Series:Gynecology Obstetrics & Reproductive Medicine
Subjects:
Online Access:https://gorm.com.tr/index.php/GORM/article/view/944
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823857415779516416
author Tolga Karacan
Huseyin Kiyak
Eser Ozyurek
Mevlide San
Engin Oral
author_facet Tolga Karacan
Huseyin Kiyak
Eser Ozyurek
Mevlide San
Engin Oral
author_sort Tolga Karacan
collection DOAJ
description Objective: Endometriosis is a common gynecological condition that affects many women of reproductive age worldwide and is a major cause of pain and infertility. Treatment of endometriosis can be either surgical, aiming to restore normal anatomy by removing endometriotic lesions, or hormonal. Various medical treatments with different doses, formulations, delivery systems, and regimens have been tested. The main objective of this study was to compare the efficacy and tolerability of dienogest and dienogest plus ethinylestradiol on endometriosis-related pain. Additionally, the effects on endometrioma size were examined. Study Design: A total of 81 patients with clinically diagnosed endometrioma, who had chronic pelvic pain, dysmenorrhea, or deep dyspareunia between January 2015 and December 2018 were studied retrospectively. The patients were divided into two main groups: continuous oral dienogest (n=43) (Visanne®, 2 mg/day) and continuous oral dienogest plus ethinylestradiol (n=38) (Dienille®, 2 mg/0.03 mg/day). The intensity of pain symptoms was evaluated before therapy, then after 3 and 6 months of treatment using a 10-point numerical rating scale (0 = no pain and 10 = worst possible pain) (NRS) provided to the patients in advance. Results: The pain scores related to chronic pelvic pain decreased 36% for dienogest and 49% for dienogest plus ethinylestradiol (p<0.05) and scores for dysmenorrhea decreased 38% and 44% respectively (p<0.05) at 6 months, significantly lower than before treatment. At the 6-month follow-up, a 28% decrease in the pain scores related to deep dyspareunia in the dienogest group was statistically significant. Although the dienogest plus ethinylestradiol group also decreased by 20%, the difference was not significant. There was no significant difference in endometrioma size between the two groups at the 6-month follow-up (dienogest and dienogest plus ethinylestradiol; 24.2±17.5 mm vs. 27.5±19.1 mm, respectively; p=0.42). Conclusion: Upon analysis of our 6 months of clinical data, estrogen-progestin and a progestin alone seem to be of similar efficacy for the temporary treatment of endometriosis-related pain. The dienogest plus ethinylestradiol combination was slightly less effective on deep dyspareunia but was still well tolerated. Similarly, the two hormonal regimens posed no superiority over one another with regard to endometrioma size reduction.
format Article
id doaj-art-49b257fe38ab4dd4841a598cb5ed30cc
institution Kabale University
issn 1300-4751
2602-4918
language English
publishDate 2020-12-01
publisher Medical Network
record_format Article
series Gynecology Obstetrics & Reproductive Medicine
spelling doaj-art-49b257fe38ab4dd4841a598cb5ed30cc2025-02-11T21:10:42ZengMedical NetworkGynecology Obstetrics & Reproductive Medicine1300-47512602-49182020-12-0126310.21613/GORM.2019.944Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-PainTolga Karacan0Huseyin Kiyak1Eser Ozyurek2Mevlide San3Engin Oral4University of Health Sciences, Bagcilar Research and Education Hospital, IstanbulKanuni Sultan Suleyman Research and Education Hospital, University of Health Sciences, IstanbulUniversity of Health Sciences, Bagcilar Research and Education Hospital, IstanbulUniversity of Health Sciences, Bagcilar Research and Education Hospital, IstanbulDeparment of Obstetrics and Gynecology, Istanbul University, Cerrahpasa Medical Faculty, Istanbul Objective: Endometriosis is a common gynecological condition that affects many women of reproductive age worldwide and is a major cause of pain and infertility. Treatment of endometriosis can be either surgical, aiming to restore normal anatomy by removing endometriotic lesions, or hormonal. Various medical treatments with different doses, formulations, delivery systems, and regimens have been tested. The main objective of this study was to compare the efficacy and tolerability of dienogest and dienogest plus ethinylestradiol on endometriosis-related pain. Additionally, the effects on endometrioma size were examined. Study Design: A total of 81 patients with clinically diagnosed endometrioma, who had chronic pelvic pain, dysmenorrhea, or deep dyspareunia between January 2015 and December 2018 were studied retrospectively. The patients were divided into two main groups: continuous oral dienogest (n=43) (Visanne®, 2 mg/day) and continuous oral dienogest plus ethinylestradiol (n=38) (Dienille®, 2 mg/0.03 mg/day). The intensity of pain symptoms was evaluated before therapy, then after 3 and 6 months of treatment using a 10-point numerical rating scale (0 = no pain and 10 = worst possible pain) (NRS) provided to the patients in advance. Results: The pain scores related to chronic pelvic pain decreased 36% for dienogest and 49% for dienogest plus ethinylestradiol (p<0.05) and scores for dysmenorrhea decreased 38% and 44% respectively (p<0.05) at 6 months, significantly lower than before treatment. At the 6-month follow-up, a 28% decrease in the pain scores related to deep dyspareunia in the dienogest group was statistically significant. Although the dienogest plus ethinylestradiol group also decreased by 20%, the difference was not significant. There was no significant difference in endometrioma size between the two groups at the 6-month follow-up (dienogest and dienogest plus ethinylestradiol; 24.2±17.5 mm vs. 27.5±19.1 mm, respectively; p=0.42). Conclusion: Upon analysis of our 6 months of clinical data, estrogen-progestin and a progestin alone seem to be of similar efficacy for the temporary treatment of endometriosis-related pain. The dienogest plus ethinylestradiol combination was slightly less effective on deep dyspareunia but was still well tolerated. Similarly, the two hormonal regimens posed no superiority over one another with regard to endometrioma size reduction. https://gorm.com.tr/index.php/GORM/article/view/944DienogestDienogest plus ethinylestradiolEndometriosisHormonal treatment
spellingShingle Tolga Karacan
Huseyin Kiyak
Eser Ozyurek
Mevlide San
Engin Oral
Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain
Gynecology Obstetrics & Reproductive Medicine
Dienogest
Dienogest plus ethinylestradiol
Endometriosis
Hormonal treatment
title Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain
title_full Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain
title_fullStr Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain
title_full_unstemmed Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain
title_short Comparison of the Efficacy and Tolerability of Dienogest and Dienogest Plus Ethinylestradiol on Endometriosis Related-Pain
title_sort comparison of the efficacy and tolerability of dienogest and dienogest plus ethinylestradiol on endometriosis related pain
topic Dienogest
Dienogest plus ethinylestradiol
Endometriosis
Hormonal treatment
url https://gorm.com.tr/index.php/GORM/article/view/944
work_keys_str_mv AT tolgakaracan comparisonoftheefficacyandtolerabilityofdienogestanddienogestplusethinylestradiolonendometriosisrelatedpain
AT huseyinkiyak comparisonoftheefficacyandtolerabilityofdienogestanddienogestplusethinylestradiolonendometriosisrelatedpain
AT eserozyurek comparisonoftheefficacyandtolerabilityofdienogestanddienogestplusethinylestradiolonendometriosisrelatedpain
AT mevlidesan comparisonoftheefficacyandtolerabilityofdienogestanddienogestplusethinylestradiolonendometriosisrelatedpain
AT enginoral comparisonoftheefficacyandtolerabilityofdienogestanddienogestplusethinylestradiolonendometriosisrelatedpain